extended-release guanfacine hydrochloride (SPD503)
SPD503-314
Phase 3 small_molecule completed
Quick answer
extended-release guanfacine hydrochloride (SPD503) for Attention-Deficit/Hyperactivity Disorder is a Phase 3 program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).
Program details
- Company
- TAKEDA PHARMACEUTICAL CO LTD
- Indication
- Attention-Deficit/Hyperactivity Disorder
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed